177 related articles for article (PubMed ID: 38514636)
21. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
[TBL] [Abstract][Full Text] [Related]
22. microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
Wangzhou K; Fu W; Li M; Lu Z; Lai Z; Liu C; Tan Y; Hao C
Oral Dis; 2023 Mar; 29(2):491-504. PubMed ID: 34152066
[TBL] [Abstract][Full Text] [Related]
23. Lysine specific demethylase 1 inhibitor alleviated lipopolysaccharide/D-galactosamine-induced acute liver injury.
Wang X; Sun Y; Fu Y; Wu H; Chen Y; Ye Y; Zhou Q; He L; Zhou E; Wang J; Yang Z
Eur J Pharmacol; 2022 Oct; 932():175227. PubMed ID: 36007605
[TBL] [Abstract][Full Text] [Related]
24. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.
Boulding T; McCuaig RD; Tan A; Hardy K; Wu F; Dunn J; Kalimutho M; Sutton CR; Forwood JK; Bert AG; Goodall GJ; Malik L; Yip D; Dahlstrom JE; Zafar A; Khanna KK; Rao S
Sci Rep; 2018 Jan; 8(1):73. PubMed ID: 29311580
[TBL] [Abstract][Full Text] [Related]
25. The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.
Liu H; Wei J; Sang N; Zhong X; Zhou X; Yang X; Zhang J; Zuo Z; Zhou Y; Yang S; Du J; Zhao Y
Med Oncol; 2021 Sep; 38(10):124. PubMed ID: 34491469
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner.
Lin Y; Kang T; Zhou BP
Cell Cycle; 2014; 13(11):1708-16. PubMed ID: 24675890
[TBL] [Abstract][Full Text] [Related]
27. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression.
Mei YP; Zhu XF; Zhou JM; Huang H; Deng R; Zeng YX
Cancer Lett; 2006 Feb; 232(2):189-98. PubMed ID: 16458115
[TBL] [Abstract][Full Text] [Related]
28. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y
Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895
[TBL] [Abstract][Full Text] [Related]
29. The histone LSD1 demethylase in stemness and cancer transcription programs.
Amente S; Lania L; Majello B
Biochim Biophys Acta; 2013 Oct; 1829(10):981-6. PubMed ID: 23684752
[TBL] [Abstract][Full Text] [Related]
30. TSPAN8 promotes colorectal cancer cell growth and migration in LSD1-dependent manner.
Zhang HS; Liu HY; Zhou Z; Sun HL; Liu MY
Life Sci; 2020 Jan; 241():117114. PubMed ID: 31790687
[TBL] [Abstract][Full Text] [Related]
31. Crucial Role of Lysine-Specific Histone Demethylase 1 in RANKL-Mediated Osteoclast Differentiation.
Ding M; Chen Z; Cho E; Park SW; Lee TH
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835016
[TBL] [Abstract][Full Text] [Related]
32. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
Lee DY; Salahuddin T; Iqbal J
Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
[TBL] [Abstract][Full Text] [Related]
33. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.
Sakane C; Okitsu T; Wada A; Sagami H; Shidoji Y
Biochem Biophys Res Commun; 2014 Jan; 444(1):24-9. PubMed ID: 24406160
[TBL] [Abstract][Full Text] [Related]
35. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells.
Hino S; Kohrogi K; Nakao M
Cancer Sci; 2016 Sep; 107(9):1187-92. PubMed ID: 27375009
[TBL] [Abstract][Full Text] [Related]
36. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1.
Zhang W; Cheng J; Diao P; Wang D; Zhang W; Jiang H; Wang Y
Br J Cancer; 2020 Feb; 122(4):528-538. PubMed ID: 31848446
[TBL] [Abstract][Full Text] [Related]
37. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.
Guasparri I; Bubman D; Cesarman E
Blood; 2008 Apr; 111(7):3813-20. PubMed ID: 18230756
[TBL] [Abstract][Full Text] [Related]
38. LSD1: more than demethylation of histone lysine residues.
Perillo B; Tramontano A; Pezone A; Migliaccio A
Exp Mol Med; 2020 Dec; 52(12):1936-1947. PubMed ID: 33318631
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus latent membrane protein-1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy.
Lin HC; Chang Y; Chen RY; Hung LY; Chen PC; Chen YP; Medeiros LJ; Chiang PM; Chang KC
Cancer Sci; 2021 Apr; 112(4):1589-1602. PubMed ID: 33525055
[TBL] [Abstract][Full Text] [Related]
40. Class I lysine deacetylases promote glucocorticoid-induced transcriptional repression through functional interaction with LSD1.
Patrick NM; Griggs CA; Icenogle AL; Gilpatrick MM; Kadiyala V; Jaime-Frias R; Smith CL
J Steroid Biochem Mol Biol; 2017 Mar; 167():1-13. PubMed ID: 27645313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
